Four-Year Entecavir Treatment in Nucleoside-Naïve HBeAg(+) Patients: Results from Studies ETV-022 and -901
Zeitschrift Fur Gastroenterologie(2008)
摘要
Aims: Entecavir (ETV) 0.5mg demonstrated superior virologic suppression compared to lamivudine (LVD) 100mg in study ETV-022. One hundred and eighty-three entecavir-treated patients from ETV-022 enrolled in rollover study ETV-901. We present efficacy and safety results in a cohort of patients from ETV studies -022 and -901 who received a total of 4 years of therapy with ETV.
更多查看译文
关键词
four-year
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要